New Health Sciences


News

October 2010 – Hemanext Research to be Presented at AABB Conference

Dr. Larry Dumont of Dartmouth-Hitchcock Medical Center will present a paper by Dr. Dumont and Dr. Tatsuro Yoshida (New Health Sciences’ Hemanext R&D director) entitled CO2 effects during anaerobic storage of RBC at the AABB’s Annual Meeting and Expo on October 9, 2010 in Baltimore, MD.

The abstract was published in Transfusion (Transfusion 2010; 50 Sup: S14-010C).

Click here to read the abstract.


October 2010 – New Health Sciences Announces Commercial Launch and General Availability of WebTCD

BETHESDA, Maryland, September 30, 2010—New Health Sciences Inc. has officially launched WebTCD, a workflow and medical records management system, that transforms the clinical utility and economic characteristics of Transcranial Doppler ultrasound by significantly reducing the time spent by physicians and staff to prepare, review and process TCD examinations and dramatically improving and expanding physician access to past exam results.

September 24, 2010 – New Health Sciences Files Investigational New Device (IND) Application with US Food and Drug Administration

New Health Sciences has filed its IND application for the Hemanext Anaerobic Storage Platform (HASP) with the U.S. Food and Drug Administration.

HASP is a disposable device that de-oxygenates red blood cells at the point of collection and stores the red cells anaerobically for up to 12 weeks. NHSi has demonstrated that this innovative new technology can deliver higher-quality, more physiologic blood, with an improved capacity to deliver oxygen and more deformable red blood cells for better capillary perfusion, and extend by 50 percent or more the shelf life of stored red blood cells.

FDA’s approval of the IND, which is expected by mid-November 2010, will enable NHSi to launch human trials of the prototype HASP disposable device at Dartmouth-Hitchcock Medical Center.

NHSi is developing and testing the prototype HASP device with funding support from an NIH Phase II SBIR grant.


August 23, 2010 – NHSi Completes Development of Prototype HASP Disposable Device, Launches In Vitro Trial at Darmouth-Hitchcock Medical Center

New Health Sciences has completed development and manufacturing of its prototype Hemanext Anaerobic Storage Platform (HASP) disposable device and has commenced an in vitro trial of the new device in Dr. Larry Dumont’s laboratory at DHMC. The objective of the in vitro trial is to demonstrate that RBC stored anaerobically with HASP are of higher quality (i.e., better physiologic characteristics) than conventionally stored RBC after 3, 6, and 9 weeks storage.

Following the successful conclusion of the in vitro trial, NHSi and DHMC plan an in vivo trial to demonstrate that, after 3 and 6 weeks of storage, a significantly higher 24 hour post-transfusion recovery can be achieved compared to conventionally stored blood; and that such RBCs can achieve a 9-week shelf life.

NHSi is developing and testing the prototype HASP device with funding support from an NIH Phase II SBIR grant.


August 2010 – National Blood Foundation Awards $75,000 Grant for Microvascular Analyzer Research

The National Blood Foundation has awarded Tulane University (Dr. Sergey Shevkoplyas) a $75,000 grant for phase I research and development of NHSi’s Microvascular Analyzer (MVA) technology. MVA is a network of micro-channels etched into a disposable plastic cartridge that simulates the human microvascular system to measure red blood cells’ ability to perfuse the end organ capillary systems. NHSi is developing MVA as a “release test” that can be used to test the quality of each unit of red blood cells prior to transfusion.

The research will measure and compare red cells ability to perfuse the MVA for conventionally stored and anaerobically stored red cells. The anaerobically stored cells will be prepared and stored using NHSi’s Hemanext Anaerobic Storage Platform (HASP). NHSi and Tulane will attempt to correlate the HASP red cells’ MVA results with the HASP red cells’ 24-hour recovery measured in NHSi’s NIH-funded SBIR Phase II HASP program at Dartmouth-Hitchcock Medical Center.


June 2010 – Hemanext Technology and Research Cited by Blood Transfusion Editorial

In an editorial published in the journal Blood Transfusion, Dr. James AuBuchon (President and CEO, Puget Sound Blood Bank, and Professor of Medicine and Laboratory Medicine, Univeristy of Washington) and Dr. Giancarlo Maria Liumbruno (Research and Clinical Immunohaematology, Transfusion Medicine and Clinical Pathology at the Hospital Fatebenfratelli, Isola, Tiberina), conclude that the “[Hemanext] anaerobic storage approach has the potential to enhance the quality of RBC storage and transfusion therapy and will help us to improve and optimise the care of patients in the near future.”

Click here to read the complete editorial.


June 2010 – Hemanext Research Presented at the XXXIX Convegno Nazionale di Studi di Medicina Transfusionale in Milan, Italy

New Health Sciences’ Hemanext R&D director, Dr. Tatsuro Yoshida presented a talk entitled “New Models for Blood Storage” at the XXXIX Convegno Nationale di Studi di Medicina Transfusionale, in Milan, Italy.

The review of anaerobic RBC storage, co-authored with Dr. Sergey S. Shevkoplyas of Tulane University, has been accepted for publication in the upcoming issue of the journal Blood Transfusion.

Click here to read the complete article.


May 2010 – NHSi Launches WebTCD Beta Evaluation with University of Miami

NHSi has launched a three-month beta evaluation of the latest version of its WebTCD medical workflow and records management system with the Department of Neurology at the University of Miami’s Miller School of Medicine.

The objectives of the beta evaluation are to demonstrate that WebTCD’s quality and performance meet the rigorous standards of a live clinical environment and to quantify the clinical and economic benefits delivered by the system.

Following successful conclusion of the beta evaluation, NHSi intends to commercially launch the WebTCD solution in September 2010.


January 22, 2010 – NHSi Closes Financing

New Health Sciences has closed a $2.6 million Series A financing raised from a combination of new and existing private investors.

NHSi will use the new capital to fund completion of the development and to launch commercialization of its Hemodynamic and Hemanext technologies.


October 2009 – Hemanext Research Presented at the Blood and Proteomics Conference in Viterbo, Italy

New Health Sciences’ Hemanext R&D director, Dr. Tatsuro Yoshida presented the results of NHSi’s research in the field of anaerobic storage of red blood cells at the Blood and Proteomics Conference in Viterbo, Italy.


May 26, 2009—New Health Sciences Inc.

(NHSi) has won a two-year award of $1.9 million from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) to develop a groundbreaking blood-storage system.

The project aims to develop the Hemanext Anaerobic Storage Platform, which delivers higher quality blood for transfusion therapy and extends the shelf life of blood for transfusion.

Click here to read the complete press release.


March 2009 – Hemanext Trial Results Published in Transfusion

The results of NHSi’s Phase I Hemanext Anaerobic Storage Platform (HASP) trial have been accepted for publication in Transfusion. The article entitled “Anaerobic Storage of Red Blood Cells in a Novel Additive Solution Improves in vivo recovery” will appear in the March 2009 issue.

The trial was funded by a Phase I SBIR grant from the National Heart, Lung and Blood Institute. The trial was performed at the Dartmouth-Hitchcock Medical Center under the supervision of Dr. James AuBuchon, Dr. Larry Dumont, and Dr. Tatsuro Yoshida.

Click here to read the complete article.


December 1, 2008 – Hemanext Patent Application 10/377,178 for Microvascular Network Device Allowed by US Patent and Trademark Office

On December 1, 2008 the NHSi received notification from the USPTO that Hemanext patent application number 10/377,178 for Microvascular Network Device was allowed for issuance as a patent.

The Microvascular Network Device is a novel technology that measures the ability of red blood cells to deform and perfuse the capillary beds to deliver oxygen to end organs.

With the addition of the Microvascular Network Device patent, NHSi now owns a portfolio of 7 Hemanext-related patents and 7 HVA-related patents.


October 2008 – Hemanext Trial Results Published in Transfusion

The results of NHSi’s Phase I Hemanext Anaerobic Storage Platform (HASP) trial have been accepted for publication in Transfusion. The article entitled “The effects of additive solution pH and metabolic rejuvenation on anaerobic storage of red cells” will appear in the October 2008 issue.

The trial was funded by a Phase I SBIR grant from the National Heart, Lung and Blood Institute. The trial was performed at the Dartmouth-Hitchcock Medical Center under the supervision of Dr. James AuBuchon, Dr. Larry Dumont, and Dr. Tatsuro Yoshida.

Click here to read the complete article.


October 2008 – Hemanext trial results to be presented at AABB

The results of NHSi’s Phase I Hemanext Anaerobic Storage Platform (HASP) trial have been accepted for presentation at the AABB conference in October 2008 in San Diego, CA.

The trial was funded by a Phase I SBIR grant from the National Heart, Lung and Blood Institute. The trial was performed at the Dartmouth-Hitchcock Medical Center under the supervision of Dr. James AuBuchon, Dr. Larry Dumont, and Dr. Tatsuro Yoshida.

Dr. Yoshida, Director, Research and Development at New Health Sciences will present the trial results…

Click here to see the complete presentation.


January 2007 – NHSi and Wake Forest Complete Asymptomatic Reference Trial

New Health Sciences and Wake Forest University have completed collection HVA data from a 364-subject asymptomatic, demographically-balanced cohort of asymptomatic subjects. The data was collected under an prospective, IRB-approved protocol under the supervision of Dr. Charles Tegeler at Wake Forest University. The data from this trial forms the core of a unique reference data set of asymptomatic subjects stratified by age, sex and race.


December 2007 – FDA clears NHSi to market HVA

On December 22, 2007, the FDA cleared NHSi’s Hemodymanic Vascular Analysis (HVA) for commercial sale as an aid in the diagnosis of neurovascular disease.


August 2007 – NHSi awarded $280,000 contract from major pharmaceutical company

New Health Sciences, inc has been awarded a $280,000 contract to utilize its Hemodynamic Vascular Analysis to measure the cerebral vascular response to a new drug under development for the treatment of dementia.


June 3, 2007 – NHSi and the Cleveland Clinic Complete Normal Pressure Hydrocephalus Study

NHSi and the Cleveland Clinic Foundation have completed a prospective, clinical trial of 30 patients undergoing extended CSF trial lumbar drainage for the diagnosis.

In thirty patients who presented with ventriculomegaly and one or more of the triad symptoms (gait impairment, cognitive impairment, and urinary incontinence), TCD measures were obtained from 23 vessel segments and/or ensembles of segments in 16 CSF drainage “responders” and 14 “non-responders” immediately before and after 36-hour, lumbar CSF drainage procedure for the diagnosis of NPH.

TCD data were analyzed using Hemodynamic Vascular Analysis (HVA) to measure differences in the HVA/TCD parameters (MFV, PSV, SA, and PI) between “responders” and “non-responsders” at presentation and percent change in the HVA/TCD parameters with CSF trial drainage.

The HVA data showed significant differences in between responders and non-responders both at presentation and after CSF removal. HVA showed a unique pattern of specific vessel sites that was significantly different between responders and non-responders in combination and individually. HVA was able to classify treatment responders from non-responders with 81.8% sensitivity and 75% specificity.


January 1, 2006 – HVA in Altitude Sickness Research to be published in Wilderness and Environmental Medicine.

NHSi’s research elucidating the mechanism underlying altitude sickness has been accepted for publication in the journal of Wilderness and Environmental Medicine in an article entitled “Cerebrovascular Dynamics and Vascular Endothelial Growth Factor in Acute Mountain Sickness”.

Click here to read the complete article.


Contact Us

New Health Sciences, Inc.
6903 Rockledge Drive, Suite 230
Bethesda, MD 20817-1818
Map

(301) 493-5550 (telephone)
(301) 493-4360 (fax)

Contact Us